Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (234) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (26) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (21) Apply Team member filter
- Videos (16) Apply Videos filter
- Analyst (12) Apply Analyst filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Investor contact (6) Apply Investor contact filter
- Event (3) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Oxford Biomedica plc interim results for the six months ended 30 June 2020
Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell thera
Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration
Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therap
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therap